New York-based Ovid Therapeutics and Healx entered a strategic partnership to investigate the compound gaboxadol to treat Fragile X Syndrome (FXS).
Zynerba Pharmaceuticals’ experimental cannabis-based gel Zygel was not statistically significant in improving aberrant behavior when compared to a placebo in patients with a neurological disorder called Fragile X syndrome.
